Unknown

Dataset Information

0

Development of a claims-based risk-scoring model to predict emergency department visits in older patients receiving anti-neoplastic therapy.


ABSTRACT: This study developed and validated a risk-scoring model, with a particular emphasis on medication-related factors, to predict emergency department (ED) visits among older Korean adults (aged 65 and older) undergoing anti-neoplastic therapy. Utilizing national claims data, we constructed two cohorts: the development cohort (2016-2018) with 34,642 patients and validation cohort (2019) with 10,902 patients. The model included a comprehensive set of predictors: demographics, cancer type, comorbid conditions, ED visit history, and medication use variables. We employed the least absolute shrinkage and selection operator (LASSO) regression to refine and select the most relevant predictors. Out of 120 predictor variables, 12 were integral to the final model, including seven related to medication use. The model demonstrated acceptable predictive performance in the validation cohort with a C-statistic of 0.76 (95% CI 0.74-0.77), indicating reasonable calibration. This risk-scoring model, after further clinical validation, has the potential to assist healthcare providers in the effective management and care of older patients receiving anti-neoplastic therapy.

SUBMITTER: Suh Y 

PROVIDER: S-EPMC10794170 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of a claims-based risk-scoring model to predict emergency department visits in older patients receiving anti-neoplastic therapy.

Suh Yewon Y   Jeong Jonghyun J   Park Soh Mee SM   Heo Kyu-Nam KN   Lee Mee Yeon MY   Ah Young-Mi YM   Kim Jin Won JW   Kim Kwang-Il KI   Lee Ju-Yeun JY  

Scientific reports 20240117 1


This study developed and validated a risk-scoring model, with a particular emphasis on medication-related factors, to predict emergency department (ED) visits among older Korean adults (aged 65 and older) undergoing anti-neoplastic therapy. Utilizing national claims data, we constructed two cohorts: the development cohort (2016-2018) with 34,642 patients and validation cohort (2019) with 10,902 patients. The model included a comprehensive set of predictors: demographics, cancer type, comorbid co  ...[more]

Similar Datasets

| S-EPMC5905698 | biostudies-literature
| S-EPMC10833462 | biostudies-literature
| S-EPMC10366948 | biostudies-literature
| S-EPMC7606545 | biostudies-literature
| S-EPMC8367131 | biostudies-literature
| S-EPMC4822667 | biostudies-literature
| S-EPMC8242842 | biostudies-literature
| S-EPMC8174209 | biostudies-literature
| S-EPMC11225288 | biostudies-literature
| S-EPMC8519030 | biostudies-literature